LATE-STAGE PRECLINICAL DEVELOPMENT OF TEIXOBACTIN TO TREAT DRUG-RESISTANT INFECTIONS

$4,499,475FY2025Defense Health AgencyDOD

Novobiotic Pharmaceuticals, Llc, Cambridge MA

Investigators